Back to results
US 7,842,297 B2Granted
Immunisation against chlamydia trachomatis
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsGuido Grandi, Giulio Ratti
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsGuido Grandi, Giulio Ratti
Estimating the term…
The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a Chlamydia specific immune response. In another example, a method of raising an antibody specific for Chlamydia trachomatis elementary bodies (EB) is provided in which a protein of the present invention is administered to a patient.
A method of eliciting an immune response to a protein comprising the amino acid sequence SEQ ID NO:61, comprising administering to a patient an effective amount of a protein comprising the amino acid sequence SEQ ID NO:61, whereby an immune response to the administered protein is elicited.
A method of raising an antibody to a protein comprising the amino acid sequence SEQ ID NO:61, comprising administering to a patient a protein comprising the amino acid sequence SEQ ID NO:61, whereby an antibody that binds to the administered protein is raised.
A composition comprising a protein in substantially pure form, wherein the protein comprises the amino acid sequence SEQ ID NO:61.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Medicinal preparations containing antigens or antibodies: chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
Drugs for genital or sexual disorders
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antimycotics
Term ended 1 Mar 2025 (estimated)
This application incorporates by reference the contents of a 841 KB text file created Jun. 12, 2008 and named “SN—12043465_sequence_listing.txt,” which is the sequence listing for this application.
This invention is in the field of immunisation against chlamydia infection, in particular against infection by Chlamydia trachomatis.
Chlamydia are obligate intracellular parasites of eukaryotic cells which are responsible for endemic sexually transmitted infections and various other disease syndromes. They occupy an exclusive eubacterial phylogenic branch, having no close relationship to any other known organisms—they are classified in thir own order (Chlamydiales) which contains a single family (Chlamydiaceae) which in turn contains a single genus (Chlamydia, also referred to as Chlamydophila). A particular characteristic of the Chlamydiae is their unique life cycle, in which the bacterium alternates between two morphologically distinct forms: an extracellular infective form (elementary bodies, EB) and an intracellular non-infective form (reticulate bodies, RB). The life cycle is completed with the reorganization of RB into EB, which leave the disrupted host cell ready to infect further cells.
FIGS. 1 to 44 show data from examples 1 to 44. Where a figure is of a gel, lane 1 is at the left of the figure.
For Western Blots, two samples were tested for each protein. The left lane in a pair used membrane strips stained with pre-immune sera whilst the right lane used membrane strips stained with immune sera. In the Western blots in FIGS. 1 to 5, 35B, 37B, 38B and 39, markers are at 66, 45, 30, 20.1 and 14.4 kDa. In the Western blots in FIGS. 6 to 16, 20B, 23C, 24D, 27E, 38A, 40, 41, 42 and 43 markers are at 172.6, 111.4, 79.6, 61.3, 49.0, 36.4, 24.7, 19.2 and 13.1 kDa.
In the Western Blots in FIGS. 1 to 5, lanes 2 and 3 show control sera raised against GST-fusion control antigens. In the Western blots in FIGS. 1 to 5, lanes 4 and 5 contain control sera raised against His-tagged control antigens.
Low molecular weight markers are run in lane 1 of the purification gels.